Assessment of the Level of Protein C in Hospitalized Iraqi Patients with COVID-19 and its Correlation with Hematological and Inflammatory Markers

Hind Shaker Al-Mamoori; Majid Hameed Ahmed; Taha Yaseen Shammar Al-Nafie; Zaid Al-Attar

doi:10.3889/oamjms.2022.8937

Authors

Hind Shaker Al-Mamoori Department of Pathology, College of Medicine, Al-Nahrain University, Baghdad, Iraq
Majid Hameed Ahmed Department of Physiology, College of Medicine, Al-Nahrain University, Baghdad, Iraq
Taha Yaseen Shammar Al-Nafie Department of Lab, Al-Imamain Al-Kadhimain Teaching Hospital, Baghdad, Iraq
Zaid Al-Attar HLA Unit, Al-Kindy College of Medicine, University of Baghdad, Baghdad, Iraq

DOI:

https://doi.org/10.3889/oamjms.2022.8937

Keywords:

COVID-19, Protein C, D-Dimer, Coagulopathy

Abstract

BACKGROUND: COVID-19 coagulopathy manifests by elevation of certain marker of active coagulation as fibrinogen and this increment associated with increased markers of inflammations.

AIM: To measure protein C (PC) level in hospitalized patients with COVID-19 and to find a possible correlation with hematological and inflammatory markers.

PATIENTS AND METHODS: Seventy-five hospitalized Iraqi adult patients with COVID-19 were included in a descriptive cross-sectional research. PC, D-dimer, and erythrocyte sedimentation rate (ESR) blood samples were collected, and further information was received from patient’s records. Statistical analysis was conducted using SPSS version 23 and Microsoft Office Excel 2019.

RESULTS: Mean age of 75 patients included in the study was 60.13 ± 14.65 years. Sixty-two (62.7%) of patients exhibited neutrophilia, whereas 41 had lymphopenia (54.7%). High ratio of neutrophil/lymphocyte (N/L) was seen in 66 (88.0%), eosinopenia was seen in 46 (61.3%), high lactate dehydrogenase level was seen 68 (90.7%), serum ferritin was high in 66 (88.0%), and high level of C-reactive protein was seen in 68 (90.7%), increased ESR was seen in 69 (92.0%) and high level of D-dimer was seen in 56 (74.7%), while low level of PC was seen in 12 (16.0%) patients. PC had significant negative correlation with prothrombin and partial thromboplastin time but no significant correlation with hematological and inflammatory parameters.

CONCLUSION: COVID-19 coagulopathy is common in majority of patients which include significant changes in WBCs counts, inflammatory markers, PC, and D-dimer levels. Such changes may have a great impact on morbidity and mortality and thus need to be monitored throughout treatment and convalescence.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Griffin JH, Lyden P. COVID-19 hypothesis: Activated protein C for therapy of virus-induced pathologic thromboinflammation. Res Pract Thromb Haemost. 2020;4(4):506-9. https://doi.org/10.1002/rth2.12362 PMid:32548551 DOI: https://doi.org/10.1002/rth2.12362

Al Otair H, AlSaleh K, AlQahtany FS, Al Ayed K, Al Ammar H, Al Mefgai N, et al. The level of vWF antigen and coagulation markers in hospitalized patients with Covid-19. J Blood Med. 2021;12:809-17. https://doi.org/10.2147/jbm.s318940 PMid:34512061 DOI: https://doi.org/10.2147/JBM.S318940

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33. https://doi.org/10.1056/nejmoa2001017 PMid:31978945 DOI: https://doi.org/10.1056/NEJMoa2001017

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9. https://doi.org/10.1001/jama.2020.1585 PMid:32031570 DOI: https://doi.org/10.1001/jama.2020.1585

Liu L, Lei X, Xiao X, Yang J, Li J, Ji M. Epidemiological and clinical characteristics of patients with coronavirus disease-2019 in Shiyan city, China. Front Cell Infect Microbiol. 2020;10:284. https://doi.org/10.3389/fcimb.2020.00284 PMid:32574282 DOI: https://doi.org/10.3389/fcimb.2020.00284

Miesbach W, Makris M. COVID-19: Coagulopathy, risk of thrombosis, and the rationale for anticoagulation. Clin Appl Thromb Hemost. 2020;26:1076029620938149. https://doi.org/10.1177/1076029620938149 PMid:32677459 DOI: https://doi.org/10.1177/1076029620938149

Vajari MK, Shirin M, Pourbagheri-Sigaroodi A, Akbari ME, Abolghasemi H, Bashash D. COVID-19-related coagulopathy: A review of pathophysiology and pharmaceutical management. Cell Biol Int. 2021;45(9):1832-50. https://doi.org/10.1002/cbin.11623 PMid:33945651 DOI: https://doi.org/10.1002/cbin.11623

Liu Q, Wang RS, Qu GQ, Wang YY, Liu P, Zhu YZ, et al. Gross examination report of a COVID-19 death autopsy. Fa Yi Xue Za Zhi. 2020;36(1):21-3. https://doi.org/10.12116/j.issn.1004-5619.2020.01.005 PMid:32198987

Dahlbäck B, Villoutreix BO. Regulation of blood coagulation by the protein C anticoagulant pathway: Novel insights into structure-function relationships and molecular recognition. Arterioscler Thromb Vasc Biol. 2005;25(7):1311-20. https://doi.org/10.1161/01.atv.0000168421.13467.82 PMid:15860736 DOI: https://doi.org/10.1161/01.ATV.0000168421.13467.82

Bashash D, Hosseini-Baharanchi FS, Rezaie-Tavirani M, Safa M, Dilmaghani NA, Faranoush M, et al. The prognostic value of thrombocytopenia in COVID-19 patients; a systematic review and meta-analysis. Arch Acad Emerg Med. 2020;8(1):e75. PMid:33134971

Gupta N, Zhao YY, Evans CE. The stimulation of thrombosis by hypoxia. Thromb Res. 2019;181:77-83. https://doi.org/10.1016/j.thromres.2019.07.013 PMid:31376606 DOI: https://doi.org/10.1016/j.thromres.2019.07.013

Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS- CoV and lessons from the past. J Clin Virol. 2020;127:104362. https://doi.org/10.1016/j.jcv.2020.104362 PMid:32305883 DOI: https://doi.org/10.1016/j.jcv.2020.104362

Wang YD, Zhang SP, Wei QZ, Zhao MM, Mei H, Zhang ZL, et al. COVID-19 complicated with DIC: 2 cases report and literatures review. Zhonghua Xue Ye Xue Za Zhi. 2020;41(3):245-7. https://doi.org/10.3760/cma.j.issn.0253-2727.2020.0001 PMid:32133824

Stanne TM, Pedersen A, Gisslén M, Jern C. Low admission protein C levels are a risk factor for disease worsening and mortality in hospitalized patients with COVID-19. Thromb Res. 2021;204:13-15. https://doi.org/10.1016/j.thromres.2021.05.016 PMid:34102452 DOI: https://doi.org/10.1016/j.thromres.2021.05.016

Francischetti IM, Toomer K, Zhang Y, Jani J, Siddiqui Z, Brotman DJ, et al. Upregulation of pulmonary tissue factor, loss of thrombomodulin and immunothrombosis in SARS-CoV-2 infection. EClinicalMedicine. 2021;39:101069. https://doi.org/10.1016/j.eclinm.2021.101069 PMid:34377969 DOI: https://doi.org/10.1016/j.eclinm.2021.101069

Fan BE, Chong VC, Chan SS, Lim GH, Lim KG, Tan GB, et al. Hematologic parameters in patients with COVID-19 infection. Am J Hematol. 2020;95(6):E131-4. https://doi.org/10.1002/ajh.25774 PMid:32129508 DOI: https://doi.org/10.1002/ajh.25774

Kong M, Zhang H, Cao X, Mao X, Lu Z. Higher level of neutrophil-to-lymphocyte is associated with severe COVID-19. Epidemiol Infect. 2020;148:e139. https://doi.org/10.1017/s0950268820001557 PMid:32641174 DOI: https://doi.org/10.1017/S0950268820001557

Martín-Rojas RM, Pérez-Rus G, Delgado-Pinos VE, Domingo- González A, Regalado-Artamendi I, Alba-Urdiales N, et al. COVID-19 coagulopathy: An in-depth analysis of the coagulation system. Eur J Haematol. 2020;105(6):741-50. https://doi.org/10.1111/ejh.13501 PMid:32749010 DOI: https://doi.org/10.1111/ejh.13501

Ruscitti P, Bruno F, Berardicurti O, Acanfora C, Pavlych V, Palumbo P, et al. Lung involvement in macrophage activation syndrome and severe COVID-19: Results from a cross-sectional study to assess clinical, laboratory and artificial intelligence-radiological differences. Ann Rheum Dis. 2020;79(9):1152-5. https://doi.org/10.1136/annrheumdis-2020-218048 DOI: https://doi.org/10.1136/annrheumdis-2020-218048

PMid:32719039

Spiezia L, Boscolo A, Poletto F, Cerruti L, Tiberio I, Campello E, et al. COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure. Thromb Haemost. 2020;120(6):998-1000. https://doi.org/10.1055/s-0040-1710018 PMid:32316063 DOI: https://doi.org/10.1055/s-0040-1710018

Lin S, Mao W, Zou Q, Lu S, Zheng S. Associations between hematological parameters and disease severity in patients with SARS-CoV-2 infection. J Clin Lab Anal. 2021;35(1):e23604. https://doi.org/10.1002/jcla.23604 PMid:33184946 DOI: https://doi.org/10.1002/jcla.23604

Sayad B, Afshar ZM, Mansouri F, Rahimi Z. Leukocytosis and alteration of hemoglobin level in patients with severe COVID-19: Association of leukocytosis with mortality. Health Sci Rep. 2020;3(4):e194. https://doi.org/10.1002/hsr2.194 PMid:33083572 DOI: https://doi.org/10.1002/hsr2.194

Urrechaga E, Zalba S, Otamendi I, Zabalegui MA, Galbete A, Ongay E, et al. Hemoglobin and anemia in COVID19 patients. Hematol Med Oncol 2020;5:1-4. https://doi.org/10.15761/hmo.1000217 DOI: https://doi.org/10.15761/HMO.1000217

Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan.Aretrospective observational study. Am J Respir Crit Care Med. 2020;201(11):1372-9. https://doi.org/10.1164/rccm.202003-0543oc PMid:32242738 DOI: https://doi.org/10.1164/rccm.202003-0543OC

Ish P, Malhotra N, Agrawal S, Gupta N. Relative lymphocytosis in COVID-19-a ray of hope. Adv Respir Med. 2020;88(3):287-8. https://doi.org/10.5603/arm.a2020.0098 PMid:32706115 DOI: https://doi.org/10.5603/ARM.a2020.0098

Kasinathan G, Sathar J. Haematological manifestations, mechanisms of thrombosis and anti-coagulation in COVID-19 disease: A review. Ann Med Surg (Lond). 2020;56:173-7. https://doi.org/10.1016/j.amsu.2020.06.035 PMid:32637095 DOI: https://doi.org/10.1016/j.amsu.2020.06.035

Słomka A, Kowalewski M, Żekanowska E. Coronavirus disease 2019 (COVID-19): A short review on hematological manifestations. Pathogens. 2020;9(6):493. https://doi.org/10.3390/pathogens9060493 PMid:32575786 DOI: https://doi.org/10.3390/pathogens9060493

Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta. 2020;506:145-8. https://doi.org/10.1016/j.cca.2020.03.022 PMid:32178975 DOI: https://doi.org/10.1016/j.cca.2020.03.022

Xu P, Zhou Q, Xu J. Mechanism of thrombocytopenia in COVID-19 patients. Ann Hematol. 2020;99(6):1205-8. https://doi.org/10.1007/s00277-020-04019-0 PMid:32296910 DOI: https://doi.org/10.1007/s00277-020-04019-0

Agbuduwe C, Basu S. Haematological manifestations of COVID-19: From cytopenia to coagulopathy. Eur J Haematol. 2020;105(5):540-6. https://doi.org/10.1111/ejh.13491 PMid:32663356 DOI: https://doi.org/10.1111/ejh.13491

Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71(15):762-8. https://doi.org/10.1093/cid/ciaa248 PMid:32161940 DOI: https://doi.org/10.1093/cid/ciaa248

Henry BM, Vikse J, Benoit S, Favaloro EJ, Lippi G. Hyperinflammation and derangement of renin-angiotensin- aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis. Clin Chim Acta. 2020;507:167-73. https://doi.org/10.1016/j.cca.2020.04.027 PMid:32348783 DOI: https://doi.org/10.1016/j.cca.2020.04.027

Testa S, Paoletti O, Giorgi-Pierfranceschi M, Pan A. Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients. Intern Emerg Med. 2020;15(5):751-3. https://doi.org/10.1007/s11739-020-02331-1 PMid:32297089 DOI: https://doi.org/10.1007/s11739-020-02331-1

Long H, Nie L, Xiang X, Li H, Zhang X, Fu X, et al. D-Dimer and prothrombin time are the significant indicators of severe COVID-19 and poor prognosis. Biomed Res Int. 2020;2020:6159720. https://doi.org/10.1155/2020/6159720 PMid:32596339 DOI: https://doi.org/10.1155/2020/6159720

Görlinger K, Levy JH. COVID-19-associated coagulopathy. Anesthesiology. 2021;134(3):366-9. https://doi.org/10.1097/aln.0000000000003688 PMid:33417671 DOI: https://doi.org/10.1097/ALN.0000000000003688

Tabatabai A, Rabin J, Menaker J, Madathil R, Galvagno S, Menne A, et al. Factor VIII and functional protein C activity in critically Ill patients with coronavirus disease 2019: A case series. A A Pract. 2020;14(7):e01236. https://doi.org/10.1213/xaa.0000000000001236 PMid:32539272 DOI: https://doi.org/10.1213/XAA.0000000000001236

Calderon-Lopez MT, Garcia-Leon N, Gomez-Arevalillo S, Martin- Serrano P, Matilla-Garcia A. Coronavirus disease 2019 and coagulopathy: Other prothrombotic coagulation factors. Blood Coagul Fibrinolysis. 2021;32(1):44-9. https://doi.org/10.1097/mbc.0000000000000996 PMid:33417336 DOI: https://doi.org/10.1097/MBC.0000000000000996

Mazzeffi M, Chow JH, Amoroso A, Tanaka K. Revisiting the protein C pathway: An opportunity for adjunctive intervention in COVID-19? Anesth Analg. 2020;131(3):690-693. https://doi.org/10.1213/ane.0000000000005059 PMid:32541255 DOI: https://doi.org/10.1213/ANE.0000000000005059

Faust SN, Levin M, Harrison OB, Goldin RD, Lockhart MS, Kondaveeti S, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med. 2001;345(6):408-16. https://doi.org/10.1056/nejm200108093450603 PMid:11496851 DOI: https://doi.org/10.1056/NEJM200108093450603

Chornenki NL, Dwivedi DJ, Kwong AC, Zamir N, Fox-Robichaud AE, Liaw PC, et al. Identification of hemostatic markers that define the pre-DIC state: A multi-center observational study. J Thromb Haemost. 2020;18(10):2524-31. https://doi.org/10.1111/jth.14973 PMid:32573898 DOI: https://doi.org/10.1111/jth.14973

Al-Attar Z, Jasim S, Hashim I, Badai S. Prevalence of anemia types among overweight and obese patients attending the obesity research and therapy unit at Al-Kindy college of medicine. Int Med J. 2020;24(3)435. https://doi.org/10.47723/kcmj.v13i2.98 DOI: https://doi.org/10.47723/kcmj.v13i2.98